Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
AbbVie's call options surged 2,599%, indicating institutional investors are betting on a positive Q4 earnings report and long-term growth in the metabolic health and obesity markets. The company has a history of exceeding analyst estimates and has successfully transitioned from Humira to other drugs like Skyrizi and Rinvoq. A comprehensive federal agreement also ensures the organization can focus on research and domestic manufacturing.

Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios